Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India’s Sharp Increase In Type 2 Diabetes Boon To Drug Makers

This article was originally published in PharmAsia News

Executive Summary

Makers of drugs for diabetics report a 17 percent increase in sales in the 12-month period ending in August. Diabetic drugs also have increased from 4.6 percent of the drug market in India to 5.1 percent, according to ORG IMS. The increase, according to authorities, is due to the fact India has the world's largest population of diabetics, particularly Type 2 diabetes, which is expected to afflict more than 60 million people by 2017, up from 28 million last year. The numbers have led to an increasing number of drug makers entering that sector of the market, with GlaxoSmithKline expected to launch the first molecule for treatment within two years. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel